Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Asahi Intecc Co., Ltd. (7747.T)
Aichi, JP
Asahi Intecc Co., Ltd. is a global enterprise dedicated to the research, manufacturing, and distribution of advanced medical devices. Its market reach extends across Japan, the United States, Europe, the Middle East, and China, with a significant international footprint. The company's diverse product range serves various medical specialties, including cardiology, where it supplies percutaneous transluminal coronary angioplasty (PTCA) guide wires, guiding catheters, balloon catheters, and penetration catheters. For peripheral, abdominal, and cerebrovascular systems, they provide specialized guide wires (including IVR guide wires and cerebrovascular system guide wires) and micro catheters. Additionally, Asahi Intecc produces guide wires and catheters vital for angiography procedures. Beyond its own brand, the company offers original equipment manufacturing (OEM) services for other medical device firms. It also manufactures a variety of medical and industrial components, such as element wires, stranded conductors, coils, tubes, and terminal processing products, specializing in the development and sale of ultra-fine stainless steel wire ropes and associated processed items. Founded in 1976 as Asahi Mini Rope Sales Co., Ltd., the company was renamed Asahi Intecc Co., Ltd. in July 1988 and is headquartered in Aichi, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.77% | +4.21% | -0.23% | +17.46% | +30.15% | +17.52% | +55.23% | +29.28% | +21.87% | +132.92% | +2,141.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 9 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+11.6% ★ Q1'26: +22.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-19.4% Q1'26: +376.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+28.1% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+25.1% ★ Q1'26: +35.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+19.0% ★ Q1'26: +33.1% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.1% Q1'26: -2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.29× ★ Q1'26: 0.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 14 Rev. Ana. 14 EPS Ana. |
Jun 2027 15 Rev. Ana. 15 EPS Ana. |
Jun 2028 14 Rev. Ana. 14 EPS Ana. |
Jun 2029 10 Rev. Ana. 9 EPS Ana. |
Jun 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
35.32B
est: 35.29B (+0.1%)
|
39.51B
est: 40.35B (-2.1%)
|
42.71B
est: 41.81B (+2.2%)
|
50.12B
est: 49.94B (+0.4%)
|
57.22B
est: 57.07B (+0.3%)
|
56.55B
est: 58.29B (-3.0%)
|
61.51B
est: 60.75B (+1.2%)
|
77.75B
est: 76.55B (+1.6%)
|
90.10B
est: 92.76B (-2.9%)
|
107.55B
est: 104.88B (+2.5%)
|
120.03B
est: 119.73B (+0.2%)
|
141.19B
139.24B – 142.17B
+17.9% YoY
|
154.12B
142.54B – 158.82B
+9.2% YoY
|
166.87B
166.39B – 167.34B
+8.3% YoY
|
176.31B
168.24B – 179.69B
+5.7% YoY
|
188.25B
179.64B – 191.86B
+6.8% YoY
|
| EBITDA |
9.99B
est: 10.09B (-1.0%)
|
12.29B
est: 11.54B (+6.5%)
|
13.35B
est: 11.95B (+11.7%)
|
16.56B
est: 14.28B (+16.0%)
|
18.78B
est: 16.32B (+15.1%)
|
16.79B
est: 16.67B (+0.8%)
|
17.76B
est: 17.37B (+2.3%)
|
22.61B
est: 21.89B (+3.3%)
|
26.73B
est: 26.52B (+0.8%)
|
31.86B
est: 39.94B (-20.3%)
|
40.23B
est: 45.60B (-11.8%)
|
53.77B
53.03B – 54.15B
+17.9% YoY
|
58.70B
54.29B – 60.49B
+9.2% YoY
|
63.55B
63.37B – 63.73B
+8.3% YoY
|
67.15B
64.07B – 68.44B
+5.7% YoY
|
71.70B
68.42B – 73.07B
+6.8% YoY
|
| EBIT |
7.98B
est: 6.93B (+15.2%)
|
10.00B
est: 7.92B (+26.3%)
|
10.80B
est: 8.20B (+31.6%)
|
13.67B
est: 9.80B (+39.5%)
|
15.17B
est: 11.20B (+35.4%)
|
12.45B
est: 11.44B (+8.8%)
|
12.80B
est: 11.92B (+7.3%)
|
15.13B
est: 15.02B (+0.7%)
|
18.02B
est: 18.20B (-1.0%)
|
22.14B
est: 31.03B (-28.7%)
|
30.08B
est: 35.42B (-15.1%)
|
41.77B
41.20B – 42.06B
+17.9% YoY
|
45.60B
42.17B – 46.99B
+9.2% YoY
|
49.37B
49.23B – 49.51B
+8.3% YoY
|
52.16B
49.78B – 53.16B
+5.7% YoY
|
55.70B
53.15B – 56.77B
+6.8% YoY
|
| Net Income |
5.83B
est: 5.80B (+0.5%)
|
6.91B
est: 7.76B (-10.9%)
|
7.73B
est: 8.40B (-8.1%)
|
10.04B
est: 10.46B (-4.0%)
|
11.24B
est: 12.26B (-8.3%)
|
9.18B
est: 10.26B (-10.5%)
|
9.99B
est: 9.97B (+0.2%)
|
10.86B
est: 11.52B (-5.7%)
|
13.11B
est: 14.28B (-8.2%)
|
15.81B
est: 16.52B (-4.3%)
|
12.74B
est: 11.56B (+10.2%)
|
30.72B
30.12B – 33.60B
+165.8% YoY
|
33.07B
26.77B – 37.45B
+7.6% YoY
|
36.43B
30.18B – 43.38B
+10.2% YoY
|
40.25B
37.86B – 41.25B
+10.5% YoY
|
43.58B
40.99B – 44.67B
+8.3% YoY
|
| SGA |
10.54B
est: 11.06B (-4.7%)
|
11.51B
est: 12.65B (-9.0%)
|
12.60B
est: 13.10B (-3.9%)
|
15.39B
est: 15.65B (-1.6%)
|
17.67B
est: 17.89B (-1.2%)
|
18.08B
est: 18.27B (-1.1%)
|
20.08B
est: 19.04B (+5.5%)
|
25.23B
est: 23.99B (+5.2%)
|
28.51B
est: 29.07B (-1.9%)
|
32.31B
est: 32.87B (-1.7%)
|
35.91B
est: 37.52B (-4.3%)
|
44.25B
43.64B – 44.56B
+17.9% YoY
|
48.30B
44.67B – 49.78B
+9.2% YoY
|
52.30B
52.15B – 52.45B
+8.3% YoY
|
55.26B
52.73B – 56.32B
+5.7% YoY
|
59.00B
56.30B – 60.13B
+6.8% YoY
|
| EPS |
22.73
est: 21.38 (+6.3%)
|
27.31
est: 28.57 (-4.4%)
|
30.43
est: 30.96 (-1.7%)
|
19.44
est: 38.53 (-49.6%)
|
43.29
est: 45.15 (-4.1%)
|
35.25
est: 37.78 (-6.7%)
|
38.24
est: 36.71 (+4.2%)
|
40.00
est: 42.42 (-5.7%)
|
48.25
est: 52.45 (-8.0%)
|
58.20
est: 60.16 (-3.3%)
|
46.92
est: 43.33 (+8.3%)
|
114.66
110.96 – 123.76
+164.7% YoY
|
125.43
98.62 – 137.96
+9.4% YoY
|
138.38
111.18 – 159.80
+10.3% YoY
|
148.27
139.45 – 151.96
+7.1% YoY
|
160.54
150.98 – 164.54
+8.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kenji Miyata | President & Chief Executive Officer and Vice Chairman | 97M | male |
| Kazuhito Ishihara | Dep. Supervisor of R&D of Medical Brand Biz. of Medical Div., Dep. GM of Research Div. and Director | — | male |
| Makoto Nishiuchi | GM of Medical Brand Business Unit of Medical Division, Chief Digital Officer & Executive Director | — | male |
| Mizuho Ito | GM of Corporate Strategic Office, Administration Division, CFO & Director | — | female |
| Munechika Matsumoto | Senior Executive Officer | — | male |
| Tadakazu Kato | Senior Executive Officer | — | male |
| Yo Nobuta | Senior Executive Officer | — | — |
| Yoshinori Terai | GM of New Business Development Division & Director | — | male |
| Ippei Yugawa | Head of Affiliates & Executive Officer | — | male |
| Yuichi Iizuka | Senior Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7747.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
